



Attention Physicians and Providers!

Effective October 1, 2006, Medicare will only generate the Health Insurance Portability and Accountability Act (HIPAA) compliant remittance advice – transaction 835 version 004010A1 – to all electronic remittance advice receivers. For more details, see MLN Matters article SE0656 at <http://www.cms.hhs.gov/MLNMattersArticles/downloads/SE0656.pdf>.

MLN Matters Number: SE0658

Related Change Request (CR) #: N/A

Related CR Release Date: N/A

Effective Date: N/A

Related CR Transmittal #: N/A

Implementation Date: N/A

Medicare Part B Drug Competitive Acquisition Program (CAP) Additions to Approved CAP Vendor's Drug List Effective October 1, 2006; Information On Price File Updates

Provider Types Affected

Physicians participating in the Medicare Part B Drug CAP

Impact on Providers

This Special Edition article is being provided to inform physicians participating in the CAP program that, effective October 1, 2006, drugs are being added to the CAP drug table.

Background

The list of drugs supplied under the CAP is subject to quarterly updates, and this Special Edition article is being provided by the Centers for Medicare & Medicaid Services (CMS) to inform you of additions to the CAP drug list (Per Change Request (CR) 5079, Business Rules (BRs) 5079.3 and 5079.4. For more details, see the related *MLN Matters* article, MM5079 at <http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM5079.pdf> on the CMS site.)

Effective October 1, 2006, the CAP designated carrier will add the drugs listed in the following table to the CAP drug table, and the following Healthcare Common Procedure Coding System (HCPCS) codes will be available through the CAP:

Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents.

HCP Code	Descriptor
J3240	INJECTION, THYROTROPIN ALPHA, 0.9 MG, PROVIDED IN 1.1 MG VIAL (trade name Thyrogen®)
J9160	DENILEUKIN DIFTITOX, 300 MCG (trade name: Ontak®)
J9010	ALEMTUZUMAB, 10 MG (trade name Campath®)

An updated CAP drug list which includes the drugs listed above and updates to the NDC codes available through the CAP will be posted on the Approved CAP vendor page of the CMS CAP website

(http://www.cms.hhs.gov/CompetitiveAcquisforBios/15_Aproved_Vendor.asp#TopOfPage) and on the approved CAP vendor's website (<http://www.bioscrip.com/>) on or about September 1, 2006.

Additional Information

If you have any questions, please contact your carrier at their toll-free number, which may be found on the CMS web site at:

<http://www.cms.hhs.gov/MLNProducts/downloads/CallCenterTollNumDirectory.zip>

Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents.